<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594632</url>
  </required_header>
  <id_info>
    <org_study_id>10242</org_study_id>
    <nct_id>NCT01594632</nct_id>
  </id_info>
  <brief_title>Safety,Effectiveness and Acceptability of Sino-implant II in DR</brief_title>
  <official_title>A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the contraceptive effectiveness of Sino-implant (II).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized trial to assess the contraceptive effectiveness of Sino-implant (II) and to
      compare levonorgestrel concentrations, safety and acceptability of Sino-implant (II) and
      Jadelle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">July 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the contraceptive effectiveness of Sino-implant (II) during 4 years of use.</measure>
    <time_frame>4 years</time_frame>
    <description>Pearl Index (number of pregnancies per 100 woman-years) over 4 years of use of Sino-implant (II).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the contraceptive effectiveness of Sino-implant (II) during 5 years of use</measure>
    <time_frame>5 years</time_frame>
    <description>Pearl Index over 5 years of use of Sino-implant (II) ; continuation &amp; reasons for discontinuation in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare concentrations of levonorgestrel through 5 years after insertion of Sino-implant (II) and Jadelle</measure>
    <time_frame>5 years</time_frame>
    <description>annual and cumulative probability of pregnancy during 5 years of use of Sino-implant (II);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare pharmacokinetic profiles of Sino-implant (II) and Jadelle during the first 6 months of use in a sub-group of users undergoing intensive levonorgestrel sampling</measure>
    <time_frame>5 years</time_frame>
    <description>The PK profile of LNG during the first 6 months post-insertion including the following parameters in a sub-group of users undergoing intensive LNG sampling:
Mean LNG concentrations at 6 hours, 24 hours, 48 hours, 72 hours, 7 days and 90 days post-insertion Concentration-time profiles of LNG (individual and pooled) Maximal concentration (Cmax) and time to maximal concentration (Tmax) AUC0-7 days, AUC0-1mon, AUC0-3mon and AUC0-6mon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the safety and acceptability of Sino-implant (II) and Jadelle during 5 years of use</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse event rates in both treatment groups Annual and cumulative probability of early discontinuation in both treatment groups Reasons for discontinuation in both treatment groups Responses on acceptability questionnaires in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare free levonorgestrel index through 5 years after insertion of Sino-implant (II) and Jadelle in a sub-group of approximately 150 users.</measure>
    <time_frame>5 years</time_frame>
    <description>free levonorgestrel index, estimated as the ratio of levonorgestrel to sex hormone binding globulin at various point during 5 years of product use in a sub-group of approximately 150 women.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Jadelle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contraception using Jadelle implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sino-implant (II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jadelle</intervention_name>
    <description>LNG containing subdermal contraceptive implant</description>
    <arm_group_label>Jadelle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sino-implant (II)</intervention_name>
    <description>LNG containing subdermal contraceptive implant</description>
    <arm_group_label>Sino-implant (II)</arm_group_label>
    <other_name>Zarin, Femplant, Trust, Simplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• In good general health

          -  Aged between 18 and 44 years, inclusive

          -  Not pregnant

          -  Not lactating

          -  Not wishing to become pregnant in the next five years

          -  Request long-acting reversible contraception

          -  If previously used injectable contraceptives for pregnancy prevention, be more than 9
             months since last injection of Depo-Provera and more than 3 months after the last
             injection of a combined injectable contraceptive

          -  If previously used LNG-containing oral pills or implants, be more than 1 week after
             last hormone intake or implant removal

          -  Be able to understand the information provided and to make personal decisions on
             participation

          -  Consent to participation and sign a consent form

          -  Agree and be able to return to the clinic for follow-up visits over five years

        Exclusion Criteria:

          -  acute deep venous thrombosis and/or pulmonary embolism or history of thromboembolic
             disease

          -  systemic lupus erythematosus with positive or unknown antiphospholipid antibodies

          -  unexplained vaginal bleeding

          -  current or history of breast cancer

          -  acute liver disease or cirrhosis

          -  benign or malignant tumor of the liver

          -  use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital,
             carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products
             containing St. John's Wort (Hypericum perforatum)

          -  more than one sexual partner in the last 3 months

          -  diagnosis or treatment for a sexually transmitted infection (STI) within the past 30
             days for her or partner (excluding recurrent genital herpes or condyloma)

          -  known HIV positive status for her or partner

          -  any condition (social or medical) which in the opinion of the Investigator would make
             study participation unsafe, would interfere with adherence to study requirements or
             complicate data interpretation

          -  BMI greater than or equal to 30 (for the sub-group of women with intensive LNG
             sampling)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Brache, LIC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profamilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profamilia</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE adverse event</keyword>
  <keyword>AIDS acquired immunodeficiency syndrome</keyword>
  <keyword>ALT (SGPT) alanine aminotransferase</keyword>
  <keyword>ART antiretroviral therapy</keyword>
  <keyword>AST (SGOT) aspartate aminotransferase</keyword>
  <keyword>DCF data collection forms</keyword>
  <keyword>DMC Data Monitoring Committee</keyword>
  <keyword>FDA (U.S.) Food and Drug Administration</keyword>
  <keyword>GCP Good Clinical Practice guidelines</keyword>
  <keyword>HB sAg Hepatitis B surface antigen</keyword>
  <keyword>ICH International Conference of Harmonization</keyword>
  <keyword>IND Investigational New Drug Application</keyword>
  <keyword>IRB Institutional Review Board</keyword>
  <keyword>IU International units</keyword>
  <keyword>mg milligram(s)</keyword>
  <keyword>mm3 cubic millimeter(s)</keyword>
  <keyword>PCR polymerase chain reaction</keyword>
  <keyword>SAE serious adverse event</keyword>
  <keyword>µg microgram</keyword>
  <keyword>ULN upper limit of the normal range</keyword>
  <keyword>WB Western Blot</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

